PESQUISA DE MIELOPEROXIDASE E OUTROS MARCADORES LABORATORIAIS NOS DIFERENTES GRAUS DE OBESIDADE

Abstract

Obesity has become epidemic in XXI century and it is estimated that there are about 1.4 billion overweight adults. The existing subclinical chronic inflammation in obesity is associated with increased risk of cardiovascular disease. Adipose tissue, in addition to its energy function, has endocrine role through the secretion of adipokines. In obesity, adipocytes become dysfunctional, producing excess proinflammatory adipokines at the expense of anti-inflammatory. This inflammatory process is the link between obesity and atherogenesis. Thus, inflammation markers are potential targets for prevention, diagnosis and treatment of atherosclerosis. Myeloperoxidase (MPO), an enzyme found primarily on neutrophils, participates on innate defense mechanisms of the body through the production of oxidizing species that have antimicrobial activity. However, these oxidants and MPO act in events that feature key role in atherogenesis, such as oxidation of LDL-cholesterol, consumption of nitric oxide and activation of proteases. Therefore, the MPO has become subject of research and many studies have shown its value as predictor of cardiac risk in certain situations. However, its usage is not yet standardized and its benchmark values are not well established for laboratory diagnosis. The aim of this study was to evaluate the levels of MPO and other biomarkers in different Body Mass Index (BMI) ranges. The results indicated significant differences between the groups in the following parameters: systolic and diastolic blood pressure, HDL-cholesterol, triglycerides/HDL rate, HDL/LDL rate and white blood cells count. Elevated levels of hs-CRP were observed in the groups with obese individuals, but no significant changes were observed to serum MPO. Therefore, serum levels of MPO did not provide information on clinically significant laboratory differentiation of groups.